CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Although marked cell growth inhibition was seen in both CD34+/CML and CD34+/Normal cells after IS3si treatment, there was a trend of greater inhibition of cell growth in the CD34+/CML fraction compared with the CD34+/Normal fraction (p = 0.060).